Regeneron Pharmaceuticals, Inc. (REGN)
852.29
+28.47
(+3.46%)
USD |
NASDAQ |
Sep 02, 16:00
850.01
-2.28
(-0.27%)
After-Hours: 19:41
Regeneron Pharmaceuticals Research and Development Expense (TTM) : 5.748B for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 5.748B |
| March 31, 2026 | 5.526B |
| December 31, 2025 | 5.306B |
| September 30, 2025 | 5.097B |
| June 30, 2025 | 4.909B |
| March 31, 2025 | 4.702B |
| December 31, 2024 | 4.635B |
| September 30, 2024 | 4.414B |
| June 30, 2024 | 4.234B |
| March 31, 2024 | 4.137B |
| December 31, 2023 | 4.004B |
| September 30, 2023 | 3.895B |
| June 30, 2023 | 3.744B |
| March 31, 2023 | 3.482B |
| December 31, 2022 | 3.250B |
| September 30, 2022 | 3.019B |
| June 30, 2022 | 2.793B |
| March 31, 2022 | 2.716B |
| December 31, 2021 | 2.622B |
| September 30, 2021 | 2.594B |
| June 30, 2021 | 2.627B |
| March 31, 2021 | 2.647B |
| December 31, 2020 | 2.499B |
| September 30, 2020 | 2.314B |
| June 30, 2020 | 2.162B |
| Date | Value |
|---|---|
| March 31, 2020 | 2.332B |
| December 31, 2019 | 2.240B |
| September 30, 2019 | 2.300B |
| June 30, 2019 | 2.348B |
| March 31, 2019 | 2.011B |
| December 31, 2018 | 2.038B |
| September 30, 2018 | 1.973B |
| June 30, 2018 | 1.943B |
| March 31, 2018 | 1.923B |
| December 31, 2017 | 1.930B |
| September 30, 2017 | 1.887B |
| June 30, 2017 | 1.910B |
| March 31, 2017 | 1.970B |
| December 31, 2016 | 1.948B |
| September 30, 2016 | 1.936B |
| June 30, 2016 | 1.826B |
| March 31, 2016 | 1.666B |
| December 31, 2015 | 1.546B |
| September 30, 2015 | 1.445B |
| June 30, 2015 | 1.363B |
| March 31, 2015 | 1.270B |
| December 31, 2014 | 1.219B |
| September 30, 2014 | 1.138B |
| June 30, 2014 | 1.027B |
| March 31, 2014 | 923.70M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| AbbVie, Inc. | 9.714B |
| Gilead Sciences, Inc. | 5.943B |
| Amgen, Inc. | 7.638B |
| Biogen, Inc. | 1.736B |